Human immunodeficiency virus type 1 reverse transcriptase mutation selection during in vitro exposure to tenofovir alone or combined with abacavir or lamivudine.
Mutations selected or deselected during passage of human immunodeficiency virus strain HXB2 or resistant variants with tenofovir (TFV), abacavir (ABC), and lamivudine (3TC) differed depending on the drug combination and virus genotype. In the wild-type virus, TFV-ABC and TFV-3TC selected K65R (with reduced susceptibility to all three inhibitors) and then Y115F. TFV-containing regimens might increase K65R selection, which confers multiple nucleoside reverse transcriptase inhibitor resistance.
Stone
Chris
C
International Clinical Virology, Medicines Research Centre, GlaxoSmithKline Research and Development, Stevenage, Hertfordshire SG1 2NY, United Kingdom.
Ait-Khaled
Mounir
M
Craig
Charles
C
Griffin
Philip
P
Tisdale
Margaret
M
D000225:Adenine / Q000031:analogs & derivatives* / Q000494:pharmacology*; D019380:Anti-HIV Agents / Q000494:pharmacology*; D003001:Cloning, Molecular; D015224:Dideoxynucleosides / Q000494:pharmacology*; D004338:Drug Combinations; D024882:Drug Resistance, Viral; D005838:Genotype; D006678:HIV / Q000187:drug effects; D054303:HIV Reverse Transcriptase / Q000235:genetics*; D006801:Humans; D019259:Lamivudine / Q000494:pharmacology*; D009154:Mutation / Q000235:genetics; D063065:Organophosphonates; D009943:Organophosphorus Compounds / Q000494:pharmacology*; D018894:Reverse Transcriptase Inhibitors / Q000494:pharmacology*; D000068698:Tenofovir; D000099227:Abacavir
D000225:Adenine; D019380:Anti-HIV Agents; D015224:Dideoxynucleosides; D004338:Drug Combinations; D054303:HIV Reverse Transcriptase; D019259:Lamivudine; D063065:Organophosphonates; D009943:Organophosphorus Compounds; D018894:Reverse Transcriptase Inhibitors; D000068698:Tenofovir; D000099227:Abacavir